In summary, the combined assessment of serum folate levels and blood cell hemoglobin content may be an accurate blood biomarker of amyloid β accumulation in the brain and may have the potential to compensate for the relative weakness of APOE as an AD biomarker. Here, APOE is linked to Alzheimer disease.